| Literature DB >> 31295423 |
Leila S Ross1, David A Fidock2.
Abstract
Intensified treatment and control efforts since the early 2000s have dramatically reduced the burden of Plasmodium falciparum malaria. However, drug resistance threatens to derail this progress. In this review, we present four antimalarial resistance case studies that differ in timeline, technical approaches, mechanisms of action, and categories of resistance: chloroquine, sulfadoxine-pyrimethamine, artemisinin, and piperaquine. Lessons learned from prior losses of treatment efficacy, drug combinations, and control strategies will help advance mechanistic research into how P. falciparum parasites acquire resistance to current first-line artemisinin-based combination therapies. Understanding resistance in the clinic and laboratory is essential to prolong the effectiveness of current antimalarial drugs and to optimize the pipeline of future medicines.Entities:
Keywords: Plasmodium; antimalarials; artemisinin; drug resistance; genetics; genomics; malaria; mutations
Mesh:
Substances:
Year: 2019 PMID: 31295423 PMCID: PMC6639022 DOI: 10.1016/j.chom.2019.06.001
Source DB: PubMed Journal: Cell Host Microbe ISSN: 1931-3128 Impact factor: 21.023